213 related articles for article (PubMed ID: 14674936)
1. Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v 1a.
Hartl A; Hochreiter R; Stepanoska T; Ferreira F; Thalhamer J
Allergy; 2004 Jan; 59(1):65-73. PubMed ID: 14674936
[TBL] [Abstract][Full Text] [Related]
2. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
[TBL] [Abstract][Full Text] [Related]
3. Prevention of birch pollen-related food allergy by mucosal treatment with multi-allergen-chimers in mice.
Hoflehner E; Hufnagl K; Schabussova I; Jasinska J; Hoffmann-Sommergruber K; Bohle B; Maizels RM; Wiedermann U
PLoS One; 2012; 7(6):e39409. PubMed ID: 22768077
[TBL] [Abstract][Full Text] [Related]
4. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen.
Hartl A; Kiesslich J; Weiss R; Bernhaupt A; Mostböck S; Scheiblhofer S; Ebner C; Ferreira F; Thalhamer J
J Allergy Clin Immunol; 1999 Jan; 103(1 Pt 1):107-13. PubMed ID: 9893193
[TBL] [Abstract][Full Text] [Related]
5. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
[TBL] [Abstract][Full Text] [Related]
6. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
[TBL] [Abstract][Full Text] [Related]
7. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma.
Tourdot S; Airouche S; Berjont N; Moussu H; Betbeder D; Nony E; Bordas-Le Floch V; Baron-Bodo V; Mascarell L; Moingeon P
Vaccine; 2013 May; 31(23):2628-37. PubMed ID: 23583462
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
[TBL] [Abstract][Full Text] [Related]
10. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
11. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy.
Repa A; Grangette C; Daniel C; Hochreiter R; Hoffmann-Sommergruber K; Thalhamer J; Kraft D; Breiteneder H; Mercenier A; Wiedermann U
Vaccine; 2003 Dec; 22(1):87-95. PubMed ID: 14604575
[TBL] [Abstract][Full Text] [Related]
12. Gene gun immunization with clinically relevant allergens aggravates allergen induced pathology and is contraindicated for allergen immunotherapy.
Scheiblhofer S; Stoecklinger A; Gruber C; Hauser-Kronberger C; Alinger B; Hammerl P; Thalhamer J; Weiss R
Mol Immunol; 2007 Mar; 44(8):1879-87. PubMed ID: 17070909
[TBL] [Abstract][Full Text] [Related]
13. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
[TBL] [Abstract][Full Text] [Related]
14. The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals.
Smole U; Radauer C; Lengger N; Svoboda M; Rigby N; Bublin M; Gaier S; Hoffmann-Sommergruber K; Jensen-Jarolim E; Mechtcheriakova D; Breiteneder H
PLoS One; 2015; 10(1):e0117904. PubMed ID: 25635684
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal IgE antibodies against birch pollen allergens: novel tools for biological characterization and standardization of allergens.
Kaul S; Scheurer S; Danz N; Schicktanz S; Vieths S; Hoffmann A
J Allergy Clin Immunol; 2003 Jun; 111(6):1262-8. PubMed ID: 12789227
[TBL] [Abstract][Full Text] [Related]
16. The influence of CpG motifs on a protein or DNA-based Th2-type immune response against major pollen allergens Bet v 1a, Phl p 2 and Escherichia coli-derived beta-galactosidase.
Hochreiter R; Hartl A; Freund J; Valenta R; Ferreira F; Thalhamer J
Int Arch Allergy Immunol; 2001; 124(1-3):406-10. PubMed ID: 11307030
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
18. Characterization of wild-type recombinant Bet v 1a as a candidate vaccine against birch pollen allergy.
Batard T; Didierlaurent A; Chabre H; Mothes N; Bussières L; Bohle B; Couret MN; Ball T; Lemoine P; Focks Tejkl M; Chenal A; Clément G; Dupont F; Valent P; Krauth MT; André C; Valenta R; Moingeon P
Int Arch Allergy Immunol; 2005 Mar; 136(3):239-49. PubMed ID: 15722633
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic and Therapeutic Effects of Oral Immunotherapy on Birch Pollen-Induced Allergic Conjunctivitis in Mice with a Rice-Based Edible Vaccine Expressing a Hypoallergenic Birch Pollen Allergen.
Ishida W; Kishimoto T; Takaiwa F; Fukuda K
Cells; 2021 Nov; 10(12):. PubMed ID: 34943868
[TBL] [Abstract][Full Text] [Related]
20. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
Möbs C; Slotosch C; Löffler H; Jakob T; Hertl M; Pfützner W
J Immunol; 2010 Feb; 184(4):2194-203. PubMed ID: 20048125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
